Eur Rev Med Pharmacol Sci 2022; 26 (7): 2511-2517
DOI: 10.26355/eurrev_202204_28488

Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis

J. Badreddine, M.H. Lee, K. Mishra, R. Pope, J.Y. Kim, S.H. Hong, S. Gupta, J.M. Song, J.I. Shin, R.A. Ghayda

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA. shinji@yuhs.ac


OBJECTIVE: The aim of this study is to compare the risk of venous thromboembolic events (VTE) between patients suspending and continuing estrogen therapy perioperatively, in male to female gender-affirming surgery (vaginoplasty).

MATERIALS AND METHODS: The authors conducted a systematic review and meta-analysis of existing research on male to female gender-affirming study, which compared the risk of VTE among the usage of estrogen perioperatively.

RESULTS: A total of 209 studies were identified as potentially eligible among PubMed, Embase, and Cochrane library databases. Among the studies, 191 studies were excluded due to their abstract inappropriateness. Out of the remaining 18 studies, only 3 articles were eligible and were finally included. Meta-analysis was performed and showed odds ratio of 0.77 (95% CI: 0.04, 14.01).

CONCLUSIONS: Perioperative estrogen therapy does not increase VTE risk on male to female gender-affirming surgery. Therefore, estrogen therapy may be continued perioperatively in vaginoplasty. More prospective studies are needed.

Free PDF Download

To cite this article

J. Badreddine, M.H. Lee, K. Mishra, R. Pope, J.Y. Kim, S.H. Hong, S. Gupta, J.M. Song, J.I. Shin, R.A. Ghayda
Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 7
Pages: 2511-2517
DOI: 10.26355/eurrev_202204_28488